Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Aurigene Discovery Technologies Limited currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners, indicating a specific ratio of reviewers to pending matters. Despite this distribution, the portfolio is concentrated within 1 distinct art unit, suggesting a narrow technical focus for the current workload.
Examiner BURKETT, DANIEL JOHN is identified as the busiest examiner for the company, currently overseeing 1 pending office action. This single action is part of the total pending workload for the portfolio. The presence of multiple distinct examiners across only 1 art unit implies that while the technology is specialized, different perspectives within that unit are being applied to the applications.
Practitioners should prepare for consistent art unit policies even as they navigate different examiner preferences. The limited number of pending actions suggests a highly manageable prosecution pipeline at this stage. This concentration in a single distinct art unit allows for a unified strategy regarding technical arguments and prior art interpretations. The applicant can focus on building a consistent body of evidence that satisfies the specific requirements of this administrative group. This approach helps in maintaining a cohesive narrative across all pending applications in the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKETT, DANIEL JOHN | 1 | 62.6% | +33.2% |
| LEE, CHIHYI NMN | 1 | 33.7% | +60.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18835518 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | BURKETT, DANIEL JOHN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18835518 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | BURKETT, DANIEL JOHN | — |
| 18257962 | COCRYSTAL OF A CDK INHIBITOR | LEE, CHIHYI NMN | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18835518 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | BURKETT, DANIEL JOHN | — | §102§112 | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18257962 | COCRYSTAL OF A CDK INHIBITOR | LEE, CHIHYI NMN | 1628 | §103§112DP | Non-Final OA | — | Pending | Jun 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial